Interpace Biosciences: Slumps on internal probe, delay in quarterly filing
17/08/2020 11:37
** Diagnostic test maker's IDXG.O shares drop 19.6% to
$4.65 premarket - top percentage decliners across U.S. exchanges
** Company says its audit committee has begun an internal
investigation into certain billing and compliance matters, which
would likely delay filing of its quarterly report with U.S.
regulators urn:newsml:reuters.com:*:nFWN2FG18M
** In July 2020, IDXG received letters from several
employees, one of whom has left the company, concerning the
matters being investigated - IDXG
** Stock up over 15% this year, as of last close
(Reporting by Manas Mishra in Bengaluru)
((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780,
outside U.S. +91 806749 2709;))